Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis

Molecular Pharmacology

Volumn 50, Issue 3, 1996, Pages 573-582

  Eliasson, Erik ^a,b   Kenna, J Gerald ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CYTOCHROME P450; HALOTHANE;

ANESTHESIA; ANESTHESIA MECHANISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HEPATITIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIBODY FORMATION; AUTOANTIBODIES; AUTOANTIGENS; CELL LINE; CELL MEMBRANE; CRICETINAE; CYTOCHROME P-450 CYP2E1; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALOTHANE; HEPATITIS, TOXIC; HUMANS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TRANSFECTION;

EID: 0029786269     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kenna, J. G., and J. M. Neuberger. Immunopathogenesis and treatment of halothane hepatitis. Clin. Immunother. 3:108-124 (1995).
2. Vergani, D., G. Mieli-Vergani, A. Alberti, J. Neuberger, A. L. W. F. Eddleston, M. Davis, and R. Williams. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med. 303:66-71 (1980).
3. 14C] halothane. J. Pharmacol. Exp. Ther. 214:721-725 (1980).
4. Kenna, J. G., J. Neuberger, and R. Williams. Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane hepatitis. J. Pharmacol. Exp. Ther. 242:733-740 (1987).
5. Kenna, J. G., H. Satoh, D. D. Christ, and L. R. Pohl. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol Exp. Ther. 245:1103-1109 (1988).
6. Kenna, J. G., J. L. Martin, and L. R. Pohl. The topography of trifluoroacetylated protein antigens in liver microsomal fractions from halothane treated rats. Biochem. Pharmacol. 44:621-629 (1992).
7. Knight, T. L., K. M. Scatchard, F. N. A. M. van Pelt, and J. G. Kenna. Sera from patients with halothane hepatitis contain antibodies to halothane-induced liver antigens which are not detectable by immunoblotting. J. Pharmacol. Exp. Ther. 270:1325-1333 (1994).
8. Kenna, J. G., J. L. Martin, H. Satoh, and L. R. Pohl. Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab. Dispos. 18:788-793 (1990).
9. Johansson, I., G. Ekström, B. Scholte, D. Puzycki, H. Jörnvall, and M. Ingelman-Sundberg. Ethanol-, fasting-, and acetone-inducible cytochromes P.-450 in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies. Biochemistry 27 :1925-1934 (1988).
10. Halpert, J. R. Multiplicity of steroid-inducible cytochromes P-450 in rat liver microsomes. Arch. Biochem. Biophys. 263:59-68 (1988).
11. Satoh, H., Y. Fukida, D. K. Anderson, V. J. Ferrans, J. R. Gilette, and L. R. Pohl. Immunological studies on the mechanism of halothane-induced hepatotoxicity: immuno-histochemical evidence of trifluoroacetylated hepatocytes. J. Pharmacol. Exp. Ther. 233:857-862 (1985).
12. Schmalix, W. A., M. Barrenscheen, R. Landsiedel, C. Janzowski, G. Eisenbrand, F. J. Gonzalez, E. Eliasson, M. Ingelman-Sundberg, M. Perchermeier, F. Wiebel, H. Greim, and J. Doehmer. Stable expression of human cytochrome P450 2E1 in V79 Chinese hamster cells. Eur. J. Pharmacol. 293:123-131 (1995).
13. Martin, J. L., J. G. Kenna, B. M. Martin, D. Thomassen, G. F. Reed, and L. R. Pohl. Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. Hepatology 18:858-863 (1993).
14. Angrand, P.-O., S. Kallenbach, M. C. Weiss, and J.-P. Rousset. An exogenous albumin promoter can become silent in dedifferentiated hepatoma variants as well as intertypic hybrids. Cell Growth Diff. 1:519-526 (1990).
15. de Waziers, I., J. Bouguet, P. H. Beaune, F. J. Gonzalez, B. Ketterer, and R. Barouki. Effects of ethanol, dexamnethasone and RU 486 on expression of cytochromes P450 2B, 2E, 3A and glutathione transferase in a rat hepatoma cell line (Fao). Pharmacogenetics 2:12-18 (1992).
16. van Pelt, F. N. A. M., and J. G. Kenna. Formation of trifluoroacetylated protein antigens in cultured rat hepatocytes exposed to halothane in vitro. Biochem. Pharmacol. 48:461-471 (1994).
17. Eliasson, E., I. Johansson, and M. Ingelman-Sundberg. Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures. Biochem. Biophys. Res. Commun. 150: 436-443 (1988).
18. Brady, J. F., D. Li, H. Ishizaki, and C. S. Yang. Effect of diallyl sulfide on rat liver microsomal nitrosamine metabolism and other monooxygenase activities. Cancer Res. 48:5937-5940 (1988).
19. Loeper, J., V. Descatoire, M. Maurice, P. Beaune, J. Belghiti, D. Houssin, F. Ballet, G. Feldmann, F. P. Guengerich, and D. Pessayre. Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology 104:203-216 (1993).
20. Lind, R. C., and A. J. Gandolfi. Concentration-dependent inhibition of halothane biotransformation in the guinea pig. Drug Metab. Dispos. 21:386-389 (1993).
21. Eliasson, E., I. Johansson, and M. Ingelman-Sundberg. Substrate-, hormone-, and cAMP-regulated cytochrome P450 degradation: Proc. Natl. Acad. Sci. USA 87:3225-3229 (1990).
22. Tierney, D. J., A. L. Haas, and D. R. Koop. Degradation of cytochrome P450 2E1: selective loss after labilization of the enzyme. Arch. Biochem. Biophys. 293:9-16 (1992).
23. Pohl, L. R., D. Thomassen, N. R. Pumford, L. E. Butler, H. Satoh, V. J. Ferrans, A. Perrone, B. M. Martin, and J. L. Martin. Hapten carrier conjugates associated with halothane hepatitis, in Biological Reactive Intermediates IV (C. Witmer, R. Snyder, and D. Jollow, eds.). Plenum Press, New York, 111-120 (1990).
24. Smith, G. C. M., J. G. Kenna, D. Harrison, D. Tew, and C. R. Wolf. Autoantibodies to hepatic carboxylesterase in halothane hepatitis. Lancet 342:963-964 (1993).
25. Song, B. J., H. V. Gelboin, S. S. Park, C. S. Yang, and F. J. Gonzalez. Complementary DNA, and protein sequences of ethanol-inducible rat and human cytochrome P-450s: transcriptional and post-transcriptional regulation of the rat enzyme. J. Biol. Chem. 261:16689-16697 (1986).
26. Hasemann, C. A., R. G. Kurumbail, S. S. Boddupalli, J. A. Peterson, and J. Deisenhofer. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 2:41-62 (1995).
27. Lecoeur, S., E. Bonierbale, D. Challine, J.-C. Gautier, P. Valadon, P. M. Dansette, R. Catinot, F. Ballet, D. Mansuy, and P. H. Beaune. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem. Res. Toxicol. 7:434-442 (1994).
28. Leeder, J. S., A. Gaedigk, X. Lu, and V. A. Cook. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol. Pharmacol. 49: 234-243 (1996).
29. Bourdi, M., M. Tinel, P. H. Beaune, and D. Pessayre. Interactions of dihydralazine with cytochromes P450 1A: a possible explanation for the appearance of anti-P450 1A2 autoantibodies. Mol. Pharmacol. 46:1287-1295 (1994).
30. McGehee, R. E., Jr., M. J. J. Ronis, R. M. Cowherd, M. Ingelman-Sundberg, and T. M. Badger. Characterization of cytochrome 450 2E1 induction in a rat hepatoma FGC-4 cell model by ethanol. Biochem. Pharmacol. 48:1823-1833 (1994).
31. Hu, Y., V. Mishin, I. Johansson, C. von Bahr, A. Cross, M. J. J. Ronis, T. M. Badger, and M. Ingelman-Sundberg. Chlormethiazole as an efficient inhibitor of cytochrome P450 2E1 expression in rat liver. J. Pharmacol. Exp. Ther. 269:1286-1291 (1994).
32. Brands, R., M. D. Snider, Y. Hino, S. S. Park, H. V. Gelboin, and J. E. Rothman. Retention of membrane proteins by the endoplasmic reticulum. J. Cell Biol. 101:1724-1732 (1985).
33. Ilyin, G. P., M. Rissel, Y. Malledant, M. Tanguy, and A. Guillouzo. Human hepatocytes express trifluoroacetylated neoantigens after in vitro exposure to halothane. Biochem. Pharmacol. 48:561-567 (1994).
34. Deleted in proof.
35. Wu, D., and A. I. Cederbaum. Presence of functionally active cytochrome P-450IIE1 in the plasma membrane of rat hepatocytes. Hepatology 15: 515-524 (1992).
36. Robin, M.-A., M. Maratrat, J. Loeper, A.-M. Durand-Schneider, M. Tinel, F. Ballet, P. Beaune, G. Feldmann, and D. Pessayre. Cytochrome P4502B follows a vesicular route to the plasma membrane in cultured rat hepatocytes. Gastroenterology 108:1110-1123 (1995).
37. Heijink, E., F. De Matteis, A. H. Gibbs, A. Davies, and I. N. H. White. Metabolic activation of halothane to neoantigens in C57B1/10 mice: immunochemical studies. Eur. J. Pharmacol. 248:15-25 (1993).
38. Yamamoto, A. M., C. Mura, C. De Lemos-Chiarandini, R. Krishnamoorthy, and F. Alvarez. Cytochrome P450IID6 recognized by LKM1 antibody is not exposed on the surface of hepatocytes. Clin. Exp. Immunol. 92:381-390 (1993).
39. Black, S. D. Membrane topology of the mammalian P450 cytochromes. FASEB J. 6:680-685 (1992).
40. Terelius, Y., K. O. Lindros, E. Albano, and M. Ingelman-Sundberg. Isozyme-specificity of cytochrome P450-mediated hepatotoxicity, in Frontiers of Biotransformation (H. Rein and K. Ruckpaul, eds.). Vol 8. Akademic Verlag, Berlin, 187-232 (1992).